| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| Other Sizes |
| Targets |
DS-18561882 targets methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a mitochondrial enzyme involved in the folate-dependent one-carbon metabolism pathway. MTHFD2 catalyzes the conversion of 10-formyl-THF to 5,10-methenyl-THF and is highly expressed in rapidly proliferating cancer cells to support nucleotide synthesis. By inhibiting MTHFD2 with high potency (IC50 = 0.0063 μM), DS-18561882 disrupts folate metabolism and nucleotide biosynthesis, leading to antitumor effects.
|
|---|---|
| ln Vitro |
When tested against the MDA-MB-231 cell line, DS18561882 (0-150 nM) yields the lowest GI50 value (140 nM)[1].
In vitro, DS-18561882 is a highly potent, isozyme-selective MTHFD2 inhibitor with an IC50 of 0.0063 μM. It also inhibits MTHFD1 activity. The compound's potent inhibition of MTHFD2 makes it a valuable tool for studying the role of one-carbon metabolism in cancer cell proliferation and survival. It can be used to investigate the dependency of cancer cells on mitochondrial folate metabolism. |
| ln Vivo |
Oral treatment of DS18561882, at doses of 30, 100, or 300 mg/kg, twice daily, suppresses tumor growth inhibition in a dosage-dependent way. In mice, the dose of 300 mg/kg totally inhibits the tumor (TGI: 67%). With oral administration of 10, 30, 100, or 300 mg/kg, DS18561882, as well as its ACU (64.6, 264, 726 μg.h/ml), Cmax (11.4, 56.5, 90.1 μg /ml), and t1/2 (2.21, 2.16, 2.32 hours) for 30 mg/kg, 100 mg/kg, and 200 mg/kg, respectively, exhibit an excellent oral pharmacokinetic profile[1]. In this article[1], DS18561882, is suspended in a 0.5% (w/v) methyl cellulose 400 solution.
In vivo, DS-18561882 shows a good oral pharmacokinetic profile and induces tumor growth inhibition in a mouse xenograft model upon oral administration. Oral treatment with DS-18561882 at doses of 30, 100, or 300 mg/kg, twice daily, suppresses tumor growth in a dose-dependent manner. The compound's oral bioavailability and in vivo efficacy support its potential for cancer research, particularly in breast cancer. |
| Enzyme Assay |
For in vitro enzyme assays, recombinant MTHFD2 or MTHFD1 protein is incubated with substrates (such as 10-formyl-THF and NADP+) in assay buffer. The test compound is added at various concentrations (0.001-1000 nM). Enzyme activity is measured by monitoring the production of NADPH or other reaction products using spectrophotometric or fluorometric methods. IC50 values are calculated by fitting dose-response curves.
|
| Cell Assay |
For cell proliferation assays, cancer cell lines (such as breast cancer cell lines) are seeded in 96-well plates and treated with DS-18561882 at concentrations ranging from 0.001-10 µM for 72-96 hours. Cell viability is assessed using CellTiter-Glo or MTT assays. IC50 values are calculated from dose-response curves. Metabolic profiling can be performed to assess the effects on one-carbon metabolism and nucleotide biosynthesis.
|
| Animal Protocol |
Animal/Disease Models: Five week old female BALB/cAJcl-nu/nu (nude) mice with MDA-MB-231 luc tumor cells (4 × 106 cells/mouse)[1]
Doses: 30, 100 or 300 mg/kg Route of Administration: Oral administration; 30, 100 or 300 mg/kg; twice (two times) daily; until day 11 Experimental Results: Suppressed tumor growth in a dose-dependent manner. For in vivo efficacy studies, immunodeficient mice are implanted with breast cancer xenografts or other tumor models. When tumors reach a predetermined size, mice are randomized and treated with DS-18561882 via oral gavage at doses of 30, 100, or 300 mg/kg twice daily. Tumor volumes are measured twice weekly. At study endpoint, tumors are collected for histological analysis and biomarker evaluation to confirm MTHFD2 inhibition and assess effects on nucleotide metabolism. |
| ADME/Pharmacokinetics |
DS-18561882 is orally available with a good oral pharmacokinetic profile. The compound is soluble in DMSO. Storage is recommended at -20°C for long-term stability. Further detailed PK parameters including half-life, Cmax, AUC, and tissue distribution would be available from the primary literature. The compound's molecular weight of 608.63 suggests it may have drug-like properties pending formulation development.
|
| Toxicity/Toxicokinetics |
Toxicological data for DS-18561882 have not been extensively reported. In preclinical studies, the compound is well-tolerated at doses up to 300 mg/kg twice daily. As a research compound, it is intended for laboratory use only and is not for human or veterinary use. Standard safety precautions should be followed when handling this compound. Comprehensive toxicology studies would be required before clinical development.
|
| References | |
| Additional Infomation |
DS-18561882 is a highly potent, isozyme-selective, orally available MTHFD2 inhibitor with an IC50 of 0.0063 μM. It inhibits MTHFD1 activity and has antitumor activity in breast cancer research. The compound shows good oral PK and tumor growth inhibition in mouse xenograft models. DS-18561882 is a research tool for studying one-carbon metabolism and cancer metabolism and is not approved for clinical use.
|
| Molecular Formula |
C28H31F3N4O6S
|
|---|---|
| Molecular Weight |
608.629156351089
|
| Exact Mass |
608.191
|
| CAS # |
2227149-22-4
|
| Related CAS # |
2227149-22-4;
|
| PubChem CID |
139486677
|
| Appearance |
White to yellow solid powder
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
42
|
| Complexity |
1190
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
S(C)(NC1C=CC(=CC=1OC(F)(F)F)C(N1CC2C(=O)OC3C(=CC=C(C=3C)N3CCN(C)[C@@H](C)C3)C=2CC1)=O)(=O)=O
|
| InChi Key |
OQKAKSSZSQPTDZ-INIZCTEOSA-N
|
| InChi Code |
InChI=1S/C28H31F3N4O6S/c1-16-14-34(12-11-33(16)3)23-8-6-20-19-9-10-35(15-21(19)27(37)40-25(20)17(23)2)26(36)18-5-7-22(32-42(4,38)39)24(13-18)41-28(29,30)31/h5-8,13,16,32H,9-12,14-15H2,1-4H3/t16-/m0/s1
|
| Chemical Name |
N-[4-[8-[(3S)-3,4-dimethylpiperazin-1-yl]-7-methyl-5-oxo-2,4-dihydro-1H-chromeno[3,4-c]pyridine-3-carbonyl]-2-(trifluoromethoxy)phenyl]methanesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~150 mg/mL (~246.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 7.5 mg/mL (12.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 7.5 mg/mL (12.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 20 mg/mL (32.86 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6430 mL | 8.2152 mL | 16.4303 mL | |
| 5 mM | 0.3286 mL | 1.6430 mL | 3.2861 mL | |
| 10 mM | 0.1643 mL | 0.8215 mL | 1.6430 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
